Novartis Sublicense Rights. The sublicensing of Novartis's rights under Section 3.1(b) will be subject to the following provisions: (i) Novartis's sublicensees shall have no right to grant further sublicenses without Alnylam's written consent, which consent shall not be unreasonably withheld or delayed; and (ii) Novartis shall be primarily liable for any failure by its sublicensees to comply with, and Novartis guarantees to Alnylam the compliance by each of its sublicensees with, all relevant restrictions, limitations and obligations in this Agreement.
Appears in 3 contracts
Samples: License Agreement (Alnylam Pharmaceuticals, Inc.), License Agreement (Alnylam Pharmaceuticals, Inc.), Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)
Novartis Sublicense Rights. The sublicensing of Novartis's rights under Section 3.1(b) 2.2 will be subject to the following provisions: (i) Novartis's sublicensees shall have no right to grant further sublicenses without Alnylam's written consent, which consent shall not be unreasonably withheld or delayed; and (ii) Novartis shall be primarily liable for any failure by its sublicensees to comply with, and Novartis guarantees to Alnylam the compliance by each of its sublicensees with, all relevant restrictions, limitations and obligations in this License Agreement.
Appears in 3 contracts
Samples: License Agreement (Alnylam Pharmaceuticals, Inc.), Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.), License Agreement (Alnylam Pharmaceuticals, Inc.)
